GRAVOL TABLETS 50 MG — DIN 00013803
DIMENHYDRINATE : 50 MG · CHURCH & DWIGHT CANADA CORP · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is GRAVOL TABLETS?
GRAVOL TABLETS 50 MG contains DIMENHYDRINATE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00013803, held by CHURCH & DWIGHT CANADA CORP, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Mar-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Dimenhydrinate cost around the world?
Dimenhydrinate is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United Arab Emirates | public | 1 | 2 | AED███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
7 pack listings across 6 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Dimenhydrinate pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Dimenhydrinate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
35 holders have a Canadian DIN containing Dimenhydrinate, across 70 DINs, of which 20 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CHURCH & DWIGHT CANADA CORP | 15 | 8 | GRAVOL CAPSULES LONG ACTING 75MG, GRAVOL CHEWABLES, GRAVOL FILMKOTE TAB 15MG, GRAVOL IM, GRAVOL IMMEDIATE RELEASE & LONG ACTING CAPLETS, +10 more | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 5 | 3 | DIMENHYDRINATE INJECTION USP, NAUSEATOL | Sourceable in Canada |
| VITA HEALTH PRODUCTS INC | 3 | 3 | ANTI-NAUSEANT, ANTI-NAUSEANT LIQUID GELS, TRAVEL TABS 50 MG | Sourceable in Canada |
| HIKMA CANADA LIMITED | 2 | 2 | DIMENHYDRINATE INJECTION USP | Sourceable in Canada |
| LABORATOIRES CONFAB INC | 2 | 2 | CONFAB DIMENHYDRINATE 100 MG, CONFAB DIMENHYDRINATE 50 MG | Sourceable in Canada |
| MEDTECH PRODUCTS INC | 3 | 1 | DRAMAMINE, DRAMAMINE MOTION SICKNESS RELIEF, GAVISCON NAUSEA | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP-DIMENHYDRINATE | Sourceable in Canada |
| PHARMASCIENCE INC | 4 | 0 | ANTI-NAUSEANT, PMS-DIMENHYDRINATE SYR 3MG/ML, PMS-DIMENHYDRINATE TAB 50MG | No marketed DIN |
| TANTA PHARMACEUTICALS INC | 4 | 0 | CHILDREN'S MOTION SICKNESS LIQ, DIMENHYDRINATE TABLETS, MOTION SICKNESS CHILDREN'S CHEWABLE TABLETS, TRAVEL TABS | No marketed DIN |
| APOTEX INC | 3 | 0 | ANTI-NAUSEANT, APO DIMENHYDRINATE TAB 50MG, DIMENHYDRINATE CAPSULES | No marketed DIN |
| ICN CANADA LTD. | 2 | 0 | TRAVAMINE SUP 50MG, TRAVAMINE TAB 50MG | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 2 | 0 | ANTI-NAUSEANT TABLET, TRAVELTABS 50MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Dimenhydrinate |
|---|---|
| ATC code | R06AA11 |
| AHFS class | 56:22.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00013803 |
|---|---|
| DIN (unpadded, as printed on some documents) | 13803 |
| Brand name | GRAVOL TABLETS |
| Generic / active ingredient | DIMENHYDRINATE : 50 MG |
| Market authorization holder | CHURCH & DWIGHT CANADA CORP |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R06AA11 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R06AA |
| Current status | MARKETED |
| Status date | 22-Mar-2021 |
| Original market date | 1980-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Dimenhydrinate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
20 of 70 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANTI-NAUSEANT | 50 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | 02241532 |
| ANTI-NAUSEANT LIQUID GELS | 50 MG | CAPSULE | VITA HEALTH PRODUCTS INC | MARKETED | 02493004 |
| CONFAB DIMENHYDRINATE 100 MG | 100 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | 00392545 |
| CONFAB DIMENHYDRINATE 50 MG | 50 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | 00392553 |
| DIMENHYDRINATE INJECTION USP | 250 MG / 5 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02435241 |
| DIMENHYDRINATE INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 00392731 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 00392537 |
| DIMENHYDRINATE INJECTION USP | 50 MG / 1 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02428954 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02536536 |
| GAVISCON NAUSEA | 50 MG | TABLET | MEDTECH PRODUCTS INC | MARKETED | 02490528 |
2 · Same class — other molecules in ATC R06AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diphenhydramine | AG-DIPHENHYDRAMINE 25 MG · AG-DIPHENHYDRAMINE 50 MG · ALLER-AIDE · ALLER-AIDE ELIXIR · +155 more | 183 | 51 | Yes |
| Dimenhydrinate | AG-DIMENHYDRINATE · ANTI-NAUSEANT · ANTI-NAUSEANT LIQUID GELS · ANTI-NAUSEANT TABLET · +56 more | 70 | 20 | Yes |
| Doxylamine, Combinations | ALOG-DOXYLAMINE/PYRIDOXINE · APO-DOXYLAMINE/B6 · DICLECTIN · PMS-DOXYLAMINE-PYRIDOXINE · +1 more | 5 | 4 | Yes |
| Diphenhydramine, Combinations | BENADRYL ALLERGY & SINUS · BUCKLEY'S NIGHTTIME COUGH & CONGESTION | 2 | 1 | Yes |
| Clemastine | TAVIST TABLETS 1MG | 1 | 0 | Not in Canada |
| Diphenylpyraline, Combinations | JAMP-COUGH SUPPOSITORIES ADULT | 1 | 0 | Not in Canada |
| Doxylamine | UNISOM-2 TABLETS | 1 | 0 | Not in Canada |
| Dimenhydrinate, Combinations | GRAVERGOL CAPSULES | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R06AX | Astemizole · Azatadine · Bilastine · Cyproheptadine · Desloratadine · +6 more | 84 | 38 |
| R06AE | Cetirizine · Cyclizine · Meclozine · Meclozine, Combinations | 69 | 27 |
| R06AB | Brompheniramine · Chlorpheniramine · Dexchlorpheniramine | 17 | 1 |
| R06AD | Alimemazine · Promethazine | 17 | 1 |
| R06AC | Tripelennamine | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is GRAVOL TABLETS called?
Also recorded in Canada as: dimenhydrinate 50 MG Oral Tablet [Wal-Dram] (US), dimenhydrinate 25 MG Oral Tablet [Airmit] (US), dimenhydrinate 25 MG Chewable Tablet [Dramamine] (US), dimenhydrinate 50 MG Oral Tablet [Dramamine] (US), dimenhydrinate 50 MG Oral Tablet [Driminate] (US), dimenhydrinate 50 MG Oral Tablet [TripTone] (US), dimenhydrinate 3 MG/ML Oral Solution [Gravol] (US), dimenhydrinate 50 MG Oral Capsule [Gravol] (US), dimenhydrinate 50 MG Oral Tablet [Gravol] (US), dimenhydrinate 50 MG Chewable Tablet [Gravol] (US), dimenhydrinate 15 MG Chewable Tablet [Gravol] (US), dimenhydrinate 50 MG Chewable Tablet [Dramamine] (US), dimenhydrinate 25 MG Chewable Tablet (US), dimenhydrinate 25 MG Oral Tablet (US), dimenhydrinate 50 MG Oral Tablet (US).
The same molecule, Dimenhydrinate, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DIZINIL | Latin | Bahrain |
| DRAMAMINE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.